Piper Sandler reissued their overweight rating on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a report issued on Wednesday, Benzinga reports. They currently have a $105.00 price objective on the stock. Several other equities research analysts have also issued reports on the stock. Wedbush reaffirmed an outperform rating and issued a $86.00 price […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus recommendation of “Buy” from the four analysts that are covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have updated their coverage on the stock in the […]
Wells Fargo & Company assumed coverage on shares of Keros Therapeutics (NASDAQ:KROS – Free Report) in a research report report published on Friday morning, MarketBeat Ratings reports. The firm issued an overweight rating and a $60.00 target price on the stock. Separately, Wedbush reiterated an outperform rating and issued a $86.00 price objective on shares […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Get Free Report) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy recommendation. The average 1-year price objective among brokers that have issued ratings on the stock […]